IP Library Granted Patent US 7,011,944
Granted Patent B2
US 7,011,944 · App. 09/982,667 · Granted Mar 14, 2006

Invasive cleavage of nucleic acids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,011,944
App. No.
09/982,667
Granted
Mar 14, 2006
Kind
B2
Abstract

The present invention relates to means for the detection and characterization of nucleic acid sequences, as well as variations in nucleic acid sequences. The present invention also relates to methods for forming a nucleic acid cleavage structure on a target sequence and cleaving the nucleic acid cleavage structure in a site-specific manner. The structure-specific nuclease activity of a variety of enzymes is used to cleave the target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof.

Claims (71)

1. A method for detecting the presence of a target nucleic acid molecule in a sample, comprising:

a) incubating a sample with a thermostable 5′ nuclease under conditions wherein a cleavage structure is formed, said cleavage structure comprising:

i) a synthetic target nucleic acid, said synthetic target nucleic acid comprising a first region and a second region, said second region downstream of and contiguous to said first region;

ii) a first nucleic acid molecule, wherein at least a portion of said first nucleic acid molecule is completely complementary to said first region of said target nucleic acid;

iii) a second nucleic acid molecule comprising a 3′ portion and a 5′ portion, wherein said 5′ portion is completely complementary to said second region of said target nucleic acid;

wherein said thermostable 5′ nuclease lacks synthesis activity, and wherein at least a portion of said first nucleic acid molecule is annealed to said first region of said synthetic target nucleic acid, and wherein at least a portion of said second nucleic acid molecule is annealed to said second region of said synthetic target nucleic acid;

b) cleaving said cleavage structure with said thermostable 5′ nuclease so as to generate non-target cleavage product; and

c) detecting the cleavage of said cleavage structure.

2. The method of claim 1 , wherein said detecting the cleavage of said cleavage structure comprises detecting said non-target cleavage product.

3. The method of claim 1 , wherein said synthetic target nucleic acid comprises an amplified nucleic acid.

4. The method of claim 3 , wherein said amplified nucleic acid is produced using a polymerase chain reaction.

5. The method of claim 1 , wherein said detecting the cleavage of said cleavage structure comprises detection of fluorescence.

6. The method of claim 1 , wherein said detecting the cleavage of said cleavage structure comprises detection of mass.

7. The method of claim 1 , wherein said detecting the cleavage of said cleavage structure comprises detection of fluorescence energy transfer.

8. The method of claim 1 , wherein said detecting the cleavage of said cleavage structure comprises detection selected from the group consisting of detection of radioactivity, luminescence, phosphorescence, fluorescence polarization, and charge.

9. The method of claim 1 , wherein said first nucleic acid molecule is attached to a solid support.

10. The method of claim 1 , wherein said second nucleic acid molecule is attached to a solid support.

11. The method of claim 1 , wherein said synthetic target nucleic acid comprises DNA.

12. The method of claim 1 , wherein said cleaving step is conducted under isothermal conditions.

13. The method of claim 1 , wherein said thermostable 5′ nuclease comprises a 5′ nuclease of a DNA polymerase.

14. The method of claim 13 , wherein said DNA polymerase is Taq DNA polymerase.

15. The method of claim 1 , wherein said 3′ portion of said second nucleic acid molecule comprises an aromatic ring.

16. The method of claim 1 , wherein said 3′ portion of said second nucleic acid molecule comprises a 3′ terminal nucleotide not complementary to said target nucleic acid.

17. The method of claim 1 , wherein said 3′ portion of said second nucleic acid molecule consists of a single nucleotide.

18. The method of claim 17 , wherein said single nucleotide is not complementary to said target nucleic acid.

19. The method of claim 17 , wherein said single nucleotide is complementary to said target nucleic acid.

20. The method of claim 6 , wherein said 3′ terminal nucleotide comprises a naturally occurring nucleotide.

21. The method of claim 16 , wherein said 3′ terminal nucleotide comprises a nucleotide analog.

22. The method of claim 1 , wherein a plurality of said first nucleic acid molecule is provided, such that said first nucleic acid molecule is in concentration excess compared to said target nucleic acid.

23. The method of claim 1 , wherein a plurality of said second nucleic acid molecule is provided, such that said second nucleic acid molecule is in concentration excess compared to said target nucleic acid.

24. The method of claim 1 , wherein said target nucleic acid and said second nucleic acid molecule form a duplex, and wherein a plurality of said first nucleic acid molecule is provided such that said first nucleic acid molecule is in concentration excess compared to said duplex.

25. The method of claim 24 , wherein said cleaving said cleavage structure comprises cleaving said first nucleic acid molecule to generate non-target cleavage product.

26. The method of claim 25 , wherein said non-target cleavage product from said first nucleic acid molecule is generated in concentration excess compared to said duplex.

27. The method of claim 1 , further comprising providing a third nucleic acid molecule complementary to a third portion of said target nucleic acid upstream of said first portion of said first target nucleic acid, wherein said cleavage structure comprises said third nucleic acid molecule.

28. The method of claim 1 , wherein said thermostable 5′ nuclease is a FEN-1 nuclease.

29. The method of claim 1 , wherein said 3′ portion of said second nucleic acid molecule is completely complementary to said target nucleic acid.

30. The method of claim 29 , wherein during said incubating, said 3′ portion of said second nucleic acid molecule partially displaces said portion of said first nucleic acid molecule that is completely complementary to said first region of said target nucleic acid.

31. A method for detecting the presence of a target nucleic acid molecule in a sample, comprising:

a) incubating a sample with a thermostable FEN-1 nuclease under conditions wherein a cleavage structure is formed, said cleavage structure comprising:

i) a synthetic target nucleic acid, said synthetic target nucleic acid comprising a first region and a second region, said second region downstream of and contiguous to said first region;

ii) a first nucleic acid molecule, wherein at least a portion of said first nucleic acid molecule is completely complementary to said first region of said target nucleic acid;

iii) a second nucleic acid molecule comprising a 3′ portion and a 5′ portion, wherein said 5′ portion is completely complementary to said second region of said target nucleic acid;

wherein at least a portion of said first nucleic acid molecule is annealed to said first region of said synthetic target nucleic acid, and wherein at least a portion of said second nucleic acid molecule is annealed to said second region of said synthetic target nucleic acid;

b) cleaving said cleavage structure with said thermostable FEN-1 nuclease so as to generate non-target cleavage product; and

c) detecting the cleavage of said cleavage structure.

32. The method of claim 31 , wherein said detecting the cleavage of said cleavage structure comprises detecting said non-target cleavage product.

33. The method of claim 31 , wherein said synthetic target nucleic acid comprises an amplified nucleic acid.

34. The method of claim 33 , wherein said amplified nucleic acid is produced using a polymerase chain reaction.

35. The method of claim 31 , wherein said detecting the cleavage of said cleavage structure comprises detection of fluorescence.

36. The method of claim 31 , wherein said detecting the cleavage of said cleavage structure comprises detection of mass.

37. The method of claim 31 , wherein said detecting the cleavage of said cleavage structure comprises detection of fluorescence energy transfer.

38. The method of claim 31 , wherein said detecting the cleavage of said cleavage structure comprises detection selected from the group consisting of detection of radioactivity, luminescence, phosphorescence, fluorescence polarization, and charge.

39. The method of claim 31 , wherein said first nucleic acid molecule is attached to a solid support.

40. The method of claim 31 , wherein said second nucleic acid molecule is attached to a solid support.

41. The method of claim 31 , wherein said synthetic target nucleic acid comprises DNA.

42. The method of claim 31 , wherein said cleaving step is conducted under isothermal conditions.

43. The method of claim 31 , wherein said 3′ portion of said second nucleic acid molecule comprises an aromatic ring.

44. The method of claim 31 , wherein said 3′ portion of said second nucleic acid molecule comprises a 3′ terminal nucleotide not complementary to said target nucleic acid.

45. The method of claim 31 , wherein said 3′ portion of said second nucleic acid molecule consists of a single nucleotide.

46. The method of claim 45 , wherein said single nucleotide is not complementary to said target nucleic acid.

47. The method of claim 45 , wherein said single nucleotide is complementary to said target nucleic acid.

48. The method of claim 44 , wherein said 3′ terminal nucleotide comprises a naturally occurring nucleotide.

49. The method of claim 44 , wherein said 3′ terminal nucleotide comprises a nucleotide analog.

50. The method of claim 31 , wherein said 3′ portion of said second nucleic acid molecule is completely complementary to said target nucleic acid.

51. The method of claim 50 , wherein during said incubating, said 3′ portion of said second nucleic acid molecule partially displaces said portion of said first nucleic acid molecule that is completely complementary to said first region of said target nucleic acid.

52. The method of claim 31 , wherein a plurality of said first nucleic acid molecule is provided, such that said first nucleic acid molecule is in concentration excess compared to said target nucleic acid.

53. The method of claim 31 , wherein a plurality of said second nucleic acid molecule is provided, such that said second nucleic acid molecule is in concentration excess compared to said target nucleic acid.

54. The method of claim 31 , wherein said target nucleic acid and said second nucleic acid molecule form a duplex, and wherein a plurality of said first nucleic acid molecule is provided such that said first nucleic acid molecule is in concentration excess compared to said duplex.

55. The method of claim 54 , wherein said cleaving said cleavage structure comprises cleaving said first nucleic acid molecule to generate non-target cleavage product.

56. The method of claim 55 , wherein said non-target cleavage product from said first nucleic acid molecule is generated in concentration excess compared to said duplex.

57. The method of claim 31 , further comprising providing a third nucleic acid molecule complementary to a third portion of said target nucleic acid upstream of said first portion of said first target nucleic acid, wherein said cleavage structure comprises said third nucleic acid molecule.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
MERGER Recorded Oct 23, 2015
From: THIRD WAVE AGBIO, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: GEN-PROBE INCORPORATED
Reel/Frame 036934/0796 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS Recorded Aug 25, 2010
From: GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT
To: HOLOGIC, INC.; R2 TECHNOLOGY, INC.; SUROS SURGICAL SYSTEMS, INC.; BIOLUCENT, LLC; DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS LIMITED PARTNERSHIP; CYTYC SURGICAL PRODUCTS II LIMITED PARTNERSHIP; CYTYC SURGICAL PRODUCTS III, INC.; CYTYC PRENATAL PRODUCTS CORP.; THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 024944/0315 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2009
From: PRUDENT, JAMES R.; HALL, JEFF G.; LYAMICHEV, VICTOR I.; BROW, MARY ANN D.; DAHLBERG, JAMES E.
To: THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 022773/0196 →
SECURITY AGREEMENT Recorded Jul 29, 2008
From: THIRD WAVE TECHNOLOGIES, INC.
To: GOLDMAN SACHS CREDIT PARTNERS L.P., AS COLLATERAL AGENT
Reel/Frame 021301/0780 →